Accelerating Medicines Partnership (AMP)-RA/SLE

Powered by ImmPort

Types of Measurements
Experimental Samples

*Download counts are from individual studies as well as AllStudies downloads.

NIAMS. NIAID, pharmaceutical companies and nonprofit organizations have formed the Accelerating Medicines Partnership (AMP) Rheumatoid Arthritis – Lupus Program to develop new ways of identifying and validating promising biological targets for diagnostics and drug development. An overview of the AMP Rheumatoid Arthritis – Lupus Program and its three research phases and a listing of the academic groups collaborating on the work are available.

The overall aim of the rheumatoid arthritis collaborative project is to collect synovial tissue from research biopsies and elective surgical procedures and blood specimens from individuals with RA to perform analytics for molecular deconstruction of RA and to compare with clinical phenotype and disease course.

The primary objective of the lupus collaborative project is to analyze kidney, blood, urine, and skin specimens from subjects with lupus nephritis and from control subjects to achieve molecular deconstruction of disease mechanisms. Specifically, the objectives are to identify disease-specific pathways that could serve as targets for novel therapies, to correlate cellular and molecular patterns in the kidney with clinical response to standard of care, and to identify blood, urine, and skin surrogates for renal profiles.

For both rheumatoid arthritis and lupus analyses the technical sites for tissue dissociation and analysis include Brigham and Women’s Hospital, and Broad Institute

The Foundation for the NIH facilitated the partnership of the academic, pharma, and non-profit organizations.

AMP Shared Data

Powered by ImmPort

Download the AMP Data Set Summary

Pubmed ID Publication Authors Supporting Data Study Title Number of Subjects

AMP Research Highlights

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways.
Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabathou S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, Mokrzycki, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium. Nat Immunol. 2019 Jul;20 7:915-927. doi: 10.1038/s41590-019-0386-1
Relevant study: SDY997

The immune cell landscape in kidneys of patients with lupus nephritis.
Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski , Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M(, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network. Nat Immunol. 2019 Jul;20 7:902-914. doi: 10.1038/s41590-019-0398-x
Relevant study: SDY997

Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry.
Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, Goodman SM, Tabechian D, Hughes LB, Salomon-Escoto K, Watts GFM, Jonsson AH(5), Rangel-Moreno J, Meednu N, Rozo C, Apruzzese W, Eisenhaure TM, Lieb DJ, Boyle DL, Mandelin AM 2nd; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium, Boyce BF, DiCarlo E, Gravallese EM, Gregersen PK, Moreland L, Firestein GS, Hacohen N, Nusbaum C, Lederer JA, Perlman H, Pitzalis C, Filer A, Holers VM, Bykerk V, Donlin LT, Anolik JH, Brenner MB, Raychaudhuri S. Nat Immunol. 2019 Jul;20 7:928-942. doi: 10.1038/s41590-019-0378-1
Relevant study: SDY998

Methods for high-dimensional analysis of cells dissociated from cyropreserved synovial tissue.
Donlin LT, Rao DA, Wei K, Slowikowski K, McGeachy MJ, Turner JD, Meednu N, Mizoguchi F, Gutierrez-Arcelus M, Lieb DJ, Keegan J, Muskat K, Hillman J, Rozo C, Ricker E, Eisenhaure TM, Li S, Browne EP, Chicoine A, Sutherby D, Noma A; Accelerating Medicines Partnership RA/SLE Network, Nusbaum C, Kelly S, Pernis AB, Ivashkiv LB, Goodman SM, Robinson WH, Utz PJ, Lederer JA, Gravallese EM, Boyce BF, Hacohen N, Pitzalis C, Gregersen PK, Firestein GS, Raychaudhuri S, Moreland LW, Holers VM, Bykerk VP, Filer A, Boyle DL, Brenner MB, Anolik JH Arthritis Res Ther. 2018 Jul 11;20(1):139. doi: 10.1186/s13075-018-1631-y.;
Relevant study: SDY999

Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and RNA Sequencing Data.
Orange DE, Agius P, DiCarlo EF, Robine N, Geiger H, Szymonifka J, McNamara M, Cummings R, Andersen KM, Mirza S, Figgie M, Ivashkiv LB, Pernis AB, Jiang CS, Frank MO, Darnell RB, Lingampali N, Robinson WH, Gravallese E; Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network, Bykerk VP, Goodman SM, Donlin LT. Arthritis Rheumatol. 2018 May;70(5):690-701. doi: 10.1002/art.40428. Epub 2018 Apr 2.
Relevant study: SDY1299

Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.
Der E, Ranabothu S, Suryawanshi H, Akat KM, Clancy R, Morozov P, Kustagi M, Czuppa M, Izmirly P, Belmont HM, Wang T, Jordan N, Bornkamp N, Nwaukoni J, Martinez J, Goilav B, Buyon JP, Tuschl T, Putterman C. JCI Insight. 2017 May 4;2(9). pii: 93009. doi: 10.1172/jci.insight.93009.
Relevant study: SDY997